腫瘍学に基づくインビボCROの世界市場分析:指示別(血液がん、固形腫瘍)、モデル別(同系モデル、患者由来異種移植片(PDX)、異種移植片)、地域別、セグメント予測、2014-2025

Grand View Researchが発行した調査報告書(GVIEW707611)
◆英語タイトル:Oncology Based In-vivo CRO Market Analysis By Indication (Blood cancer, Solid tumor), By Model (Syngeneic model, Patient Derived Xenograft (PDX), Xenograft), By Region, And Segment Forecasts, 2014-2025
◆商品コード:GVIEW707611
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2017年5月26日
◆ページ数:64
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥559,350見積依頼/購入/質問フォーム
Multi UserUSD7,950 ⇒換算¥898,350見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,124,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、腫瘍学に基づくインビボCROの世界市場について調査・分析し、腫瘍学に基づくインビボCROの世界市場動向、腫瘍学に基づくインビボCROの世界市場規模、市場予測、セグメント別腫瘍学に基づくインビボCRO市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global oncology based in-vivo CRO market is expected to reach USD 1.5 billion by 2025, according to a new report by Grand View Research, Inc. The use of Contract Research Organization (CRO) oncology services helps the manufacturers/sponsors to provide complete attention on the production capacity and at enhancing their in-house processes.Furthermore, the pressure from the increasing competition due to patent expirations, rapid growth of generics, and introduction of biosimilar equivalents are propelling the pharmaceutical companies to take the aid of such organizations. Hence, it can be predicted that the oncology based in-vivo CRO market may witness lucrative growth over the forecast period.
Another factor propelling growth is the increasing incidence of cancer, and high failure rate of existing treatment options. According to statistics published by the World Health Organization (WHO), approximately 8.2 million deaths are recorded each year from cancer, which accounts for 13.0% deaths worldwide.
Further key findings from the study suggest:
• Based on indication, solid tumors are expected to dominate the market as of 2016. Furthermore, it is anticipated to grow at the fastest CAGR owing to the factors such as growing incidence rate, augmenting research for tumors in organs such as breast, and liver, and technological advancement offered by key industry players.
• Solid tumors are analyzed by means of models such as xenograft, Patient Derived Xenografts (PDX), and syngeneic. The PDX models are expected to witness lucrative growth over the forecast period and capture over 40.0% of the market share by 2025.
• Geographic expansion into Asia Pacific countries by well-established players is anticipated to promote the fastest growth for the region. India is one the most lucrative country owing to presence of service tax exemption and venture capital based funding for CROs.
• Few of the industry players for the oncology based in-vivo CRO market are The Jackson Laboratory, Covance, Taconic Biosciences, Charles River Laboratory, EVOTEC, Wuxi AppTec, and ICON Plc.
• A common trend observed is the rising partnerships among CROs to offer bundle packages of services to sponsors. For instance, In May 2017, CRL International, Inc. announced their partnership with OcellO, established in Netherlands. According to this partnership, CRL would be utilizing the latter’s PDX model capabilities in order to expand their oncology based drug discovery service portfolio.

【レポートの目次】

Table of Content
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
1.3 Country Wise Market Calculation
1.3.1 Country wise market: Base estimates
1.3.2 Global market: CAGR calculation
1.4 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot, 2016 (USD Million)
Chapter 3 Oncology in-vivo CRO Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.2 Market Size And Growth Prospects
3.3 Market Driver Analysis
3.3.1 Focus on core competencies by the pharmaceutical players
3.3.2 Accelerating time to market
3.4 Market Restraint Analysis
3.5 Key Opportunities Prioritized
3.6 Industry Analysis Porter’s
3.7 Oncology based in-vivo CRO PESTEL Analysis
Chapter 4 Oncology in-vivo CRO Market: Indication Estimates & Trend Analysis
4.1 Oncology in-vivo CRO Market: Indication Movement Analysis
4.2 Blood cancer
4.2.1 Blood cancer market estimates and forecasts, 2014 – 2025 (USD Million)
4.3 Solid tumors
4.3.1 Solid tumors market estimates and forecasts, 2014 – 2025 (USD Million)
4.3.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2014 – 2025 (USD Million)
4.3.1.2 PDX based solid tumor market estimates and forecasts, 2014 – 2025 (USD Million)
4.3.1.3 Xenograft based solid tumor market estimates and forecasts, 2014 – 2025 (USD Million)
4.4 Other
4.4.1 Other market estimates and forecasts, 2014 – 2025 (USD Million)
Chapter 5 Oncology in-vivo CRO Market: Regional Estimates & Trend Analysis, by Indication
5.1 Oncology in-vivo CRO Market Share by Region, 2016 & 2025
5.2 North America
5.2.1 Oncology in-vivo CRO market estimates and forecasts, 2014 – 2025
5.2.2 U.S.
5.2.2.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 – 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 – 2025 (USD Million)
5.3 Europe
5.3.1 Oncology in-vivo CRO market estimates and forecasts, 2014 – 2025
5.3.2 UK
5.3.2.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 – 2025 (USD Million)
5.3.3 Germany
5.3.3.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 – 2025 (USD Million)
5.4 Asia Pacific
5.4.1 Oncology in-vivo CRO market estimates and forecasts, 2014 – 2025
5.4.2 Japan
5.4.2.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 – 2025 (USD Million)
5.4.3 China
5.4.3.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 – 2025 (USD Million)
5.5 Latin America
5.5.1 Oncology in-vivo CRO market estimates and forecasts, 2014 – 2025
5.5.2 Brazil
5.5.2.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 – 2025 (USD Million)
5.5.3 Argentina
5.5.3.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 – 2025 (USD Million)
5.6 MEA
5.6.1 Oncology in-vivo CRO market estimates and forecasts, 2014 – 2025
5.6.2 South Africa
5.6.2.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 – 2025 (USD Million)
5.6.3 Saudi Arabia
5.6.3.1 Oncology in-vivo CRO market estimates and forecasts, by indication, 2014 – 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Company Profiles
6.2.1 Charles River Laboratory (CRL)
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Product benchmarking
6.2.1.4 Strategic initiatives
6.2.2 ICON Plc
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Product benchmarking
6.2.2.4 Strategic initiatives
6.2.3 Covance
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Service benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Eurofins Scientific
6.2.4.1 Company overview
6.2.4.2 Financial performance
6.2.4.3 Product benchmarking
6.2.4.4 Strategic initiatives
6.2.5 Taconic Biosciences
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Product benchmarking
6.2.5.4 Strategic initiatives
6.2.6 Crown Bioscience
6.2.6.1 Company overview
6.2.6.2 Financial performance
6.2.6.3 Product benchmarking
6.2.6.4 Strategic initiatives
6.2.7 Toxikon, Inc.
6.2.7.1 Company overview
6.2.7.2 Financial performance
6.2.7.3 Product benchmarking
6.2.7.4 Strategic initiatives
6.2.8 WuXi AppTec
6.2.8.1 Company overview
6.2.8.2 Financial performance
6.2.8.3 Product benchmarking
6.2.8.4 Strategic Initiatives
6.2.9 EVOTEC
6.2.9.1 Company overview
6.2.9.2 Financial performance
6.2.9.3 Product benchmarking
6.2.9.4 Strategic initiatives
6.2.10 The Jackson Laboratory
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.3 Product benchmarking
6.2.10.4 Strategic initiatives

List of Figures
FIG. 1 Market summary, 2016 (USD Million)
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Pharmaceutical R&D spending, 2007 - 2012 (USD Billion)
FIG. 6 Market restraint relevance analysis (Current & future impact)
FIG. 7 Penetration & growth prospect mapping
FIG. 8 SWOT Analysis, By Factor (political & legal, economic and social)
FIG. 9 Porter’s Five Forces Analysis
FIG. 10 Oncology In-vivo CRO market indication outlook key takeaways
FIG. 11 Oncology in-vivo CRO market: Indication movement analysis
FIG. 12 Global blood cancer market, 2014 - 2025 (USD Million)
FIG. 13 Global solid tumor market, 2014 - 2025 (USD Million)
FIG. 14 Global syngeneic model based solid tumor market, 2014 - 2025 (USD Million)
FIG. 15 Global PDX model based solid tumor market, 2014 - 2025 (USD Million)
FIG. 16 Global xenograft based solid tumor market, 2014 - 2025 (USD Million)
FIG. 17 Global other tumors market, 2014 - 2025 (USD Million)
FIG. 18 Regional market place: Key takeaways
FIG. 19 Regional outlook, 2016 & 2025
FIG. 20 North America oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 21 U.S. oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 22 Canada oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 23 Europe in-vivo CRO market, 2013 - 2024 (USD Million)
FIG. 24 UK oncology in-vivo CRO market, 2013 - 2024 (USD Million)
FIG. 25 Germany oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 26 Asia Pacific oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 27 Japan oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 28 China oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 29 Latin America oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 30 Brazil oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 31 Argentina oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 32 MEA oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 33 South Africa oncology in-vivo CRO market, 2014 - 2025 (USD Million)
FIG. 34 Saudi Arabia oncology in-vivo CRO market, 2014 - 2025 (USD Million)


List of Tables
TABLE 1 North America oncology in-vivo CRO market, by region, 2014 - 2025 (USD Million)
TABLE 2 North America oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 3 U.S. oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 4 Canada oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 5 Europe oncology in-vivo CRO market, by region, 2014 - 2025 (USD Million)
TABLE 6 Europe oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 7 UK oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 8 Germany oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 9 Asia Pacific oncology in-vivo CRO market, by region, 2014 - 2025 (USD Million)
TABLE 10 Asia Pacific oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 11 Japan oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 12 China oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 13 Latin America oncology in-vivo CRO market, by region, 2014 - 2025 (USD Million)
TABLE 14 Latin America oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 15 Brazil Oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 16 Mexico oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 17 MEA oncology in-vivo CRO market, by region, 2014 - 2025 (USD Million)
TABLE 18 MEA oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 19 South Africa oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)
TABLE 20 Saudi Arabia oncology in-vivo CRO market, by indication, 2014 - 2025 (USD Million)


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 腫瘍学に基づくインビボCROの世界市場分析:指示別(血液がん、固形腫瘍)、モデル別(同系モデル、患者由来異種移植片(PDX)、異種移植片)、地域別、セグメント予測、2014-2025(Oncology Based In-vivo CRO Market Analysis By Indication (Blood cancer, Solid tumor), By Model (Syngeneic model, Patient Derived Xenograft (PDX), Xenograft), By Region, And Segment Forecasts, 2014-2025 )]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆